View all cases
UPC APP 54972/2024
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Case details
- Status—ActionProcedural applicationCategoryOther Procedural
- Parties
- Claimants
- Sanofi Mature IP
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Reps: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)Respondents- Accord Healthcare S.L.U.
- Accord Healthcare GmbH (AT)
- Accord Healthcare B.V.
- Accord Healthcare GmbH (DE)
- Accord Healthcare Italia Srl
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare AB
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Zentiva France
- Zentiva Pharma GmbH
- Zentiva, k.s.
Reps: Jules Fabre (Pinsent Mason); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing) - Division
- Munich LD
- Judges
- Matthias Zigann · Presiding Judge / Judge-Rapporteur (Munich Local Division)
- Technology
- Pharmaceutical & Medical
- Language
- —
- First decided
- Jan 7, 2025
Decisions
- 2025-01-07Application Rop305
The Munich Local Division judge-rapporteur issued a procedural order in the Sanofi pharmaceutical infringement actions (UPC_CFI_145-148/2024) granting the substitution of Sanofi-Aventis France by Sanofi Winthrop Industrie as a party following a corporate merger, under R. 310 RoP. The order addressed the allocation of court fees and costs between multiple claimant entities in relation to the French territory claims.
Legal issues:Change of party following corporate merger / dissolution (R. 310 RoP)Allocation of court fees among multiple claimantsR. 305 RoP application in pharmaceutical proceedings
Documents
- 67439B79516106DD4BFDCB68F1C1ACE9_en.pdf2025-01-07EN